RAF1 and neoplasm: Sorafenib is a multiple-target tyrosine kinase inhibitor (TKI) and can inhibit Raf-1, B-Raf, and kinase activity in the Ras/Raf/MEK/ERK signaling pathways, to further suppress tumor cell proliferation.